KIF1B (Kinesin Family Member 1B) is a motor protein that mediates anterograde transport of synaptic cargoes in neurons. It is responsible for transporting synaptic vesicles, mitochondria, and other organelles along axons. KIF1B is a monomeric kinesin-3 family member with unique processive movement properties. Mutations in KIF1B have been associated with Charcot-Marie-Tooth disease type 2A and may play a role in neurodegenerative diseases through impaired axonal transport.
KIF1B encodes a motor protein of the kinesin-3 family that functions as a plus-end directed microtubule motor. It is responsible for anterograde transport of various cargoes along neuronal axons and dendrites. Unlike most kinesins that function as dimers, KIF1B is a monomeric motor with remarkable processivity [1].
KIF1B plays critical roles in:
Mutations in KIF1B cause Charcot-Marie-Tooth disease type 2A (CMT2A1), a hereditary peripheral neuropathy characterized by progressive muscle weakness and sensory loss [2]. Additionally, KIF1B dysfunction has been implicated in Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease [3].
KIF1B encodes a motor protein of the kinesin-3 family that functions as a plus-end directed microtubule motor. It is responsible for anterograde transport of various cargoes along neuronal axons and dendrites.
KIF1B exhibits unique motor properties among kinesin family members [1][4]:
KIF1B transports multiple essential cargoes [5]:
| Cargo Type | Functional Significance |
|---|---|
| Synaptic vesicles | Neurotransmitter release |
| Mitochondria | Energy supply to distal axons |
| Synaptic proteins | Presynaptic assembly |
| RNA granules | Local translation |
| Endocytic vesicles | Membrane recycling |
KIF1B is highly expressed in:
CMT2A1 is caused by heterozygous mutations in KIF1B, resulting in a gain-of-function or dominant-negative effect that impairs axonal transport [2][6].
Clinical Features:
Pathogenic Mechanisms:
KIF1B has been implicated in ALS pathogenesis through studies showing [3][7]:
Emerging evidence suggests KIF1B may play a role in Parkinson's disease [3]:
KIF1B contains several functional domains [1][4]:
| Domain | Function |
|---|---|
| Motor domain | Microtubule binding and ATP hydrolysis |
| Coiled-coil region | Dimerization (when present) and cargo binding |
| Tail domain | Cargo recognition and binding |
| PH domain | Membrane association |
The motor domain is located at the N-terminus and contains the microtubule-binding site and ATPase activity essential for movement.
Targeting KIF1B-mediated transport offers potential therapeutic strategies [9][10]:
The study of Kif1B — Kinesin Family Member 1B has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Soppina V, et al. Dimerization of mammalian kinesin-3 motors. Nat Commun. 2019;10:3445.
Baldwin KR, et al. Axonal transport defects in ALS. Neuron. 2015;87(3):471-473.
Maeder CI, et al. Motor protein transport in neuronal axons. Brain Res Bull. 2019;153:244-255.
Sleigh JN, et al. Axonal transport and neurological disease. Nat Rev Neurol. 2019;15(12):691-703.